{"id":296681,"date":"2026-02-24T13:45:00","date_gmt":"2026-02-24T21:45:00","guid":{"rendered":"https:\/\/jthelander.com\/?p=296681"},"modified":"2026-02-24T13:45:00","modified_gmt":"2026-02-24T21:45:00","slug":"cmo-compensation-private-companies","status":"publish","type":"post","link":"https:\/\/brightturn.io\/?p=296681","title":{"rendered":"CMO Compensation at Private Companies: What It Takes to Land a Top Chief Medical Officer"},"content":{"rendered":"\n

CMO compensation at private companies is climbing as the role becomes one of the most competitive executive searches in life science. What’s a trending role for private life science companies right now? CMOs.

Last week, we hosted a Lunch & Learn webinar (video below) with Cissy Young, PhD (\u694a \u8a69\u83ef), Managing Director True Search, and she shared why CMOs have become one of the hottest executive searches for private companies.<\/p>\n\n\n\n

“Financing is starting to come back, but the investors are very disciplined and they expect that the entrepreneurs are going to be disciplined.”<\/p>\n\n\n\n

If you’re going to spend the money on a top CMO, that spend has to be justified by their ability to deliver on key clinical milestones and catalysts that drive the next round of financing.<\/p>\n\n\n\n

Using the Thelander Comp Planning Tool<\/a>, you can see how the median and 75th percentile in total cash and equity shift as a company raises capital – from <$5M through $100M+ in total financing. It gives leadership a clear way to model: how much cash and equity to offer a CMO at your current stage, how that mix evolves as you raise additional capital, and what “paying a premium” looks like in terms of real-time market data.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\n